| 000 | 00933 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250515112030.0 | ||
| 264 | 0 | _c20100122 | |
| 008 | 201001s 0 0 eng d | ||
| 022 | _a1198-0052 | ||
| 024 | 7 |
_a10.3747/co.2008.200 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLevesque, N | |
| 245 | 0 | 0 |
_aHealth management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma. _h[electronic resource] |
| 260 |
_bCurrent oncology (Toronto, Ont.) _cJan 2008 |
||
| 300 |
_a36-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 700 | 1 | _aMitchinson, K | |
| 700 | 1 | _aLawrie, D | |
| 700 | 1 | _aFedorak, L | |
| 700 | 1 | _aMacdonald, D | |
| 700 | 1 | _aNormand, C | |
| 700 | 1 | _aPouliot, J F | |
| 773 | 0 |
_tCurrent oncology (Toronto, Ont.) _gvol. 15 _gno. 1 _gp. 36-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3747/co.2008.200 _zAvailable from publisher's website |
| 999 |
_c17820325 _d17820325 |
||